Alnylam Pharmaceuticals
(NASDAQ:ALNY)
$151.22
-1.11[-0.73%]
At close: May 6
$151.22
0[0.00%]
After Hours: 4:04PM EDT
Q1 2024 Earnings were released on Thu May 2nd, before the market open
The most recent conference call was at 8:30 AM, 4 days ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Alnylam Pharmaceuticals Stock (NASDAQ:ALNY), Quotes and News Summary

Alnylam Pharmaceuticals Stock (NASDAQ: ALNY) stock price, news, charts, stock research, profile.

Open$152.820
Close$151.220
Volume / Avg.289.746K / 825.739K
Day Range149.520 - 152.820
52 Wk Range141.975 - 218.880
Market Cap$19.128B
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
0
Short Interest
2.55%
Days to Cover4.81

Recent News

Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood pressure with standard-of-care antihypertensives.
Vandana Singh
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event.
Vandana Singh
Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?
Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.
Vandana Singh
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
2
Jan
7
8
Feb
2
Mar
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
2.8
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
ALNY
LEGN

FAQ

Q

How do I buy Alnylam Pharmaceuticals (ALNY) stock?

A

You can purchase shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Alnylam Pharmaceuticals's (ALNY) competitors?

A

Other companies in Alnylam Pharmaceuticals’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Cerevel Therapeutics Hldg (NASDAQ:CERE).

Q

What is the target price for Alnylam Pharmaceuticals (ALNY) stock?

A

The latest price target for Alnylam Pharmaceuticals (NASDAQ: ALNY) was reported by Chardan Capital on Friday, May 3, 2024. The analyst firm set a price target for 225.00 expecting ALNY to rise to within 12 months (a possible 48.79% upside). 61 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Alnylam Pharmaceuticals (ALNY)?

A

The stock price for Alnylam Pharmaceuticals (NASDAQ: ALNY) is $151.22 last updated May 6, 2024 at 4:04 PM EDT.

Q

Does Alnylam Pharmaceuticals (ALNY) pay a dividend?

A

There are no upcoming dividends for Alnylam Pharmaceuticals.

Q

When is Alnylam Pharmaceuticals (NASDAQ:ALNY) reporting earnings?

A

Alnylam Pharmaceuticals’s Q2 earnings are confirmed for Thursday, August 1, 2024.

Q

Is Alnylam Pharmaceuticals (ALNY) going to split?

A

There is no upcoming split for Alnylam Pharmaceuticals.

Q

What sector and industry does Alnylam Pharmaceuticals (ALNY) operate in?

A

Alnylam Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch